Necrotizing Enterocolitis: Prevention and Prediction

  • Lebrilla, Carlito B, (PI)
  • Underwood, Mark Alan (PI)
  • Mills, David (PI)

Project: Research project

Description

DESCRIPTION (provided by applicant): Necrotizing enterocolitis (NEC) is a common and devastating disease of premature infants. Effective preventive agents and biomarkers predictive of high-risk infants are significant clinical needs. The most promising interventions shown to prevent NEC are breast milk feedings and probiotic microorganisms, although the mechanisms of action are unknown. Our proposal draws from the integrated, multi-disciplinary Milk Bioactives Consortium at the University of California Davis and includes exciting preliminary data: a clinical trial of two probiotic products in premature infants, evidence that human milk oligosaccharides selectively stimulate growth of specific bifidobacteria, and a novel potential biomarker of infant susceptibility. We hypothesize that a regimen of prebiotic oligosaccharides and/or probiotic microbes, which increases bifidobacteria colonization to mimic that of healthy term breast-fed infants, will improve infant growth and lead to an attractive regimen for larger trials of prevention of NEC. We further hypothesize that a low -defensin gene copy number polymorphism predisposes some premature infants to development of an intestinal microbiota low in bifidobacteria and the consequent deficit in normal microflora protection increases their susceptibility to NEC. Specific Aim 1 will conduct Phase 1 and Phase 2 clinical trials to identify and evaluate a preferred dietary supplement regimen to achieve a predominance of bifidobacteria in the fecal microbiota of preterm infants. Specific Aim 2 will conduct a series of in vitro experiments to (a) analyze biochemical and genetic properties of the bifidobacteria in the feces of infants receiving prebiotic oligosaccharides and/or probiotic microbes and (b) analyze the prebiotic properties of components of human milk. Specific Aim 3 will analyze the potential of a novel genetic biomarker for susceptibility to NEC: -defensin gene copy number. The proposed clinical trials and in vitro experiments are designed to answer important questions regarding the development of the intestinal microbiota, the effect of breast milk components on the developing intestinal microbiota, and the effect of changes in the intestinal microbiota on the health and growth of the premature infant. PUBLIC HEALTH RELEVANCE: Having more healthy bacteria in the intestines may improve growth and prevent infections in premature infants. By giving different doses and combinations of live healthy bacteria (probiotics) and fiber (prebiotics) to premature infants, we aim to find the best way to change the bacteria in the intestines to be more like those of healthy breast-fed term infants. The genes of premature infants who get intestinal infections may be slightly different from those who don't; we will test one group of particularly promising genes to see if that is true.
StatusFinished
Effective start/end date9/1/089/30/14

Funding

  • National Institutes of Health: $589,844.00
  • National Institutes of Health: $621,428.00
  • National Institutes of Health: $584,717.00
  • National Institutes of Health: $169,977.00
  • National Institutes of Health: $595,410.00
  • National Institutes of Health: $549,687.00

Fingerprint

Necrotizing Enterocolitis
Premature Infants
Bifidobacterium
Probiotics
Prebiotics
Human Milk
Oligosaccharides
Defensins
Gene Dosage
Biomarkers
Growth
Bacteria
Infant, Premature, Diseases
Intestines
Breast
DNA Copy Number Variations
Clinical Trials
Clinical Trials, Phase I
Microbiota
Genetic Predisposition to Disease

ASJC

  • Medicine(all)